An EUA for Casirivimab and Imdevimab for COVID-19
Date: December 28, 2020
Issue #:
1614Summary:
The FDA has issued an Emergency Use Authorization
(EUA) for Regeneron ' s investigational monoclonal
antibodies casirivimab (REGN10933) and imdevimab
(REGN10987) to be administered together by IV
infusion for treatment of mild to moderate COVID-19
in adults and pediatric patients ( ≥12 years old and
weigh ≥40 kg) who are at high risk of progressing to
severe COVID-19 and/or hospitalization (see Table 1).
Bamlanivimab (LY-CoV555; Lilly), another monoclonal
antibody, received an EUA for the same indication on
November 9, 2020.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: casirivimab COVID-19 imdevimab Source Type: research